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Outcome measures for the assessment of new antiepileptic drugs
• Fred Schobben, Yechiel Hekster and Barbara van Zw ieten-Boot
Introduction
For the approval of any new medicinal product three 
requirements are essential: quality, safety and efficacy. 
In discussions on the value of a new drug the first 
item is often underestimated, but the quality of 
design and production of any new product is a basic 
requirement. A good quality of a product means a 
guarantee for reproducible properties of the drug in 
its final formulation, including bioavailability, both 
during the pre-registration and the post-registration 
period and a safeguard against varying amounts of 
contaminating substances, throughout all produced 
and forthcoming production batches and during stor­
age up to the approved expiry date. The safety and 
efficacy parameters should be seen in positive bal­
ance: the therapeutic gain must always be more 
important than the disadvantages: toxicity, the bur­
den of treatment, adverse drug reaction and potential 
risks.
The assessment of these criteria and the decision 
making is based on the dossier, that is prepared by 
the pharmaceutical company applying for registra­
tion. The picture from such a dossier may sometimes 
differ from the properties of the product per se, as 
acknowledged by the medical professionals or from 
the scientific literature. This indeed can lead to a situ­
ation that a licence is refused for an indication that is 
widely recognised and for which the drug is success­
fully applied. However, once a product has been 
accepted in one of the EC countries, the Mutual 
Recognition Procedure might facilitate the broad 
acceptance of such a product
There is increasing international cooperation and 
coordination of activities on the field of assessment of 
medicines, both regarding the registration phase and 
post marketing surveillance. Examples of this cooper­
ation are found at the European level in the European 
Medicines Evaluation Agency (EMEA), the Committee 
on Pharmaceutical Medicinal Products (CPMP) and 
on a global level in the International Conference on 
Harmonization (ICH), a forum where authorities and 
industry from Europe, USA and japan try to harmon­
ize requirements for registration. This type of cooper­
ation increasingly leads to joint decisions.
Guidelines
In the judgement of the data in such a dossier the 
authorities and their experts often rely on guidelines, 
that are relevant for medicinal products in general or 
for specific therapeutic classes or even for subgroups 
of patients. Some of these guidelines, especially those 
issued by the national or supranational authorities, 
have been set up after extensive consultation of the 
pharmaceutical industry. For the registration of anti­
epileptic drugs some guidelines are of special import­
ance:
In the first place the Guideline on medicinal prod­
ucts for the treatment of Epileptic Disorders [1], in 
which special emphasis is given on the development 
plan of a new antiepileptic drug and the choice of
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Abstract
For the approval of any new medicinal product quality safety 
and efficacy are essential requirements. This manuscript 
focusses on the clinical development programme. For the 
investigation of antiepileptic drugs some international guide­
lines are of special importance. They are based on the know­
ledge of many experts and can be seen as a consensus on 
minimal requirements; deviations must be thoroughly justi­
fied.
In phases II and III, usually randomised, double-blind add-on 
studies versus placebo in patients with therapy-resistant sei­
zures are used to get an impression of the efficacy and cer­
tain safety issues. A clear dose-response relationship may be a 
good indication for efficacy. However, assessment of safety of 
the new product in add-on studies is difficult. Therefore com­
parative phase III monotherapy studies versus established 
antiepileptic drugs are essential to confirm the results obtai­
ned in add-on studies and are needed for a proper judge­
ment of the efficacy/safety balance.
The percentage of reduction of seizure frequency has played 
a dominating role as efficacy criterium. Nowadays preference 
is being given to the percentage responders. Which parame­
ter is the most relevant for the given group of patients and 
what change is considered clinically relevant must be tho­
roughly argued. The definition of responder should focus on 
major benefit for the patients involved.
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trials and type of patients involved and also the 
Guidelines for clinical evaluation of antiepileptic 
drugs, edited by the professionals in the epilepsy field 
itself, covered by the International League Against
Epilepsy [21
Other important guidelines are: Clinical 
Investigation of medicinal products for long-term use 
[3 4]t focussing on maintained efficacy but especially 
on safety during long-term use, and Clinical investiga­
tion of medicinal products in children [5], with major 
attention for safety. Relevant are also the Guidelines 
on good clinical practice; the EEC guideline from 
1990 [6] is now being replaced by a corresponding 
guideline from the ICH [7], These guidelines put 
major emphasis among others on methodology and 
documentation in order to improve the protection of 
patients and the credibility of data.
Although these guidelines are designed to give 
merely guidance in the planning and execution of 
investigations, their impact is much broader. Because 
they are based on the knowledge of many experts 
they may be seen as a consensus on minimal require­
ments.
This means that deviations from these guidelines 
must be thoroughly justified by authoritative experts.
Clinical studies
The evaluation process involves the chemical-phar­
maceutical data on a product, the pharmacological- 
toxicological investigations and the clinical studies. In 
this contribution major emphasis will be laid on the 
clinical development programme of a potential anti­
epileptic drug. As usual the pre-registration clinical 
studies are divided into the well known phases I, It 
and 111 studies. Although in some drug development 
plans phase II and 111 studies tend to merge, we will 
follow the classic scheme here.
PHASE I
These studies include the first administration to man, 
and are mainly set up to evaluate the safety of a new 
product. Based on all available knowledge, from in 
vitro properties, results of animal studies to human 
experience with related substances, escalating single 
dose experiments are started in healthy volunteers, 
followed by multiple dose studies.
In this phase pharmacokinetics and metabolism are 
studied in order to confirm that the preceding animal 
experiments have been the correct model to examine 
potential toxicity, and to choose the right dosing regi­
men for the experiments to come.
The next step is to evaluate the safety in epileptic 
patients. There may be a considerable difference in 
the dose tolerated by healthy volunteers and by 
patients, e.g. because of induced liver enzymes and 
drug interactions in the latter group. The studies are 
generally performed as rising dose add-on trials. 
These studies should also include pharmacokinetic 
investigation to detect interference of enzyme induc­
tion, inhibition, interactions or the role of metab­
olites. In this phase a preliminary impression of effica­
cy and certain safety issues may be obtained, in non­
blind or single blind comparison with placebo. The 
design of the studies may be dedicated to this prob­
lem: for instance a single dose study in photosensitive 
patients or a multiple dose add-on study in patients
with frequent seizures. For antiepileptic drugs to be 
administered for considerable periods of time, also in 
learning children, it is considered of importance to 
get an early impression of potential influence on cog­
nitive functions. Therefore psychometrics tests in vol­
unteers may be performed during the initial stages of 
development.
PHASE II
In this phase it should become clear whether the 
product has anticonvulsant properties in man, Usually 
randomized, double blind add-on studies versus pla­
cebo in patients with therapy-resistant seizures are 
used to demonstrate this. Here the use of an active 
comparator is hardly feasible; instead inclusion of vari­
ous fixed doses of the new product is preferable. A 
clear dose-response relationship suggests a very solid 
indication for efficacy. This type of study must define 
the dose-range for the forthcoming phase-111 efficacy 
studies. Studies on interactions with other anti-epi­
leptic drugs may be helpful in defining appropriate 
dosage selection or adjustment policy of concomitant 
treatment for the next stage of development. Specific 
attention for effects on cognitive function in patients 
is warranted as they may be quite different from 
healthy volunteers.
PHASE III
Proof of relevant efficacy can only be given by ran­
domised, double blind studies in comparison with an 
established antiepileptic drug. Add-on studies in 
patients with defined seizure types of stable frequen­
cy might prove that the drug has an efficacy compar­
able to already established antiepileptic drugs, and an 
acceptable level of toxicity. However, only if the new 
product is clearly superior to the reference drug with 
regard to seizure control will this be accepted as proof 
of clinically relevant efficacy. Proof of equivalence 
with the comparator in add-on studies is difficult: the 
study design and conduct have to fulfill a large num­
ber of conditions (see Guideline on Biostatistical 
methodology in clinical trials)[8]. Moreover assess­
ment of safety of the new product itself in add-on 
studies remains difficult
Therefore monotherapy studies are essential to 
confirm the results obtained in add-on studies in a 
much broader population and to define the ultimate 
dosage recommendation. Placebo control in these 
studies would enable to judge the absolute effect of 
the new drug but several ethical issues are raised, and 
it appears to be very difficult to include patients in 
such studies. Comparative monotherapy studies in 
previously untreated patients are of major import­
ance. In addition, monotherapy studies are essential 
to get a clear view on the intrinsic toxicity of the new 
compound. These studies are therefore required for a 
proper judgement of the efficacy/safety balance.
The acceptance of lamotrigine showed differing 
viewpoints from European authorities and experts in 
this respect. Early approval was based on a number of 
add-on studies, that showed a statistically significant 
reduction of seizures compared to placebo. This ben­
eficial result was considered of limited magnitude by 
others, and it was therefore not accepted as definite 
proof for a positive efficacy/toxicity balance. 
Subsequently a number of monotherapy studies in 
newly diagnosed patients versus well-known compar-
ator drugs were completed and some long-term 'sec­
ondary monotherapy' studies, in which lamotrigine 
was initially added to the existing therapy, that was 
sequentially withdrawn. In these studies efficacy 
appeared to be equal to comparators and reassuring 
data on long term safety were obtained. These data 
were accepted as the convincing evidence.
The duration of the double-blind treatment period 
depends on the seizure frequency of the patients 
included but should be at least 2-3 months. In order 
to demonstrate efficacy during long-term treatment 
studies on continued treatment are necessary. In 
these studies special attention must be paid to toler­
ance, for instance by comparison of average dosages 
after several periods of follow-up, and to withdrawal 
effects. For sufficient data on long-term safety studies 
should cover a minimum treatment of 100 patients 
during 1 year, or ideally 300-600 patients during 6 
months.
In special cases the requirement of monotherapy 
studies may be dropped. However, there must be a 
strong justification to do so. The recent history of 
introduction of new antiepileptic drugs has shown 
some examples: vigabatrin and felbamate. Vigabatrin 
showed an outstanding reduction of seizures in a 
number of add-on studies in partial epilepsy. 
Felbamate has been registered on a number of phase
II studies and only one add-on placebo controlled 
phase III trial. This was due to its impressive efficacy in 
patients with the Lennox Gastaut syndrome; this syn­
drome is notorious for its therapy resistent seizures. 
The reduction in atonic seizures, which can lead to 
severe wounding of the patients, was striking. This 
property led to the authorization of felbamate in
1995 by the European concertation procedure, for 
restrictive use in this type of epilepsy. Because of the 
increasing number of reports on serious haematologi- 
cal and hepatic side effects the drug was only 
approved for use in refractory cases [9].
PHASE IV
Although these trials formally fall outside the scope of 
this paper, some remarks may be useful. During this 
phase in general other seizure types than those 
focussed on during the pivotal efficacy trials are stud­
ied. Also attention is paid to treatment of specific age 
groups although children may already have been 
involved in phase III studies in special seizure types. 
Studies in children are especially important to show 
safety and to reveal potential impact on learning, 
cognition and growth.
During phase 111 patients with kidney- or liver-dys- 
function are generally excluded from participation, 
and this will mostly result in contra-indications for use 
in those patients. Specific studies are needed to prove 
safe dosage regimens for those patients; depending 
on the properties of the drug, pharmacokinetic stud­
ies may be sufficient.
Specific studies on the use of drugs during preg­
nancy are only performed in exceptional cases and 
have not been done in epilepsy; after registration data 
on this topic deserve to be collected. Post Marketing 
Surveillance of new drugs is an essential part of the 
development, and will be mainly focused on long­
term safety and rare adverse effects.
Criteria of efficacy
Although the percentage of reduction of seizure fre­
quency has played a dominating role as efficacy crite­
rium for many years, the most relevant issue is how 
much the patients benefit from treatment. Therefore 
preference is being given to the percentage respond­
ers, where responders are defined by a change con­
sidered as clinically relevant improvement This defini­
tion must be given before the start of the trial. It may 
concern a change in seizure frequency, seizure free 
interval or seizure pattern or severity relative to the 
baseline observation period. A change of seizures 
may not be the only relevant response; attention 
should also be paid to assessment of functional capac­
ity, well-being and/or cognitive functioning, though 
they are not the primary endpoints for approval. 
Which parameter is the most relevant for the given 
group of patients must be thoroughly argued, prefe­
rentially by a group of experts. They should also 
decide what change is considered clinically relevant 
For out-patients with a drivers licence years of free­
dom of seizures may be the appropriate goal, while 
for institutionalised handicapped patients the number 
of days without post-ictal drowsiness might be a 
good choice. The percentage responders should be 
calculated for the new drug, comparator and/or pla­
cebo. It must be balanced against the percentage of 
patients with a clinically relevant deterioration. As the 
percentage responders varies considerably among 
studies, analysis based on number to treat may be a 
better approach of absolute benefit [10]. Analyses 
should be done on an intention to treat basis. Special 
attention is asked for drop-outs; are they caused by 
lack of efficacy or by side effects? Even their follow up 
is very important: do they show withdrawal or 
rebound effects?
Side effects
Due to the nature of most studies, estimation of side 
effects attributable to the new drug is difficult. 
Experience during recent years has learnt that for 
some new drugs add-on studies did not correctly 
reveal the side effect pattern. Therefore lack of suffi­
cient monotherapy studies hampers the evaluation of 
adverse events. For a good judgement of the efficacy 
/toxicity balance these studies are essential. When the 
mechanism of action of a new compound is known 
this may help to evaluate some of the side effects and 
to interpret the relevance of toxic effects in animal 
studies. Unfortunately this is not the case for most 
antiepileptic drugs.
Overall judgement
After all relevant data on quality, safety and efficacy 
have been evaluated a general judgement on approv­
al has to be made by licensing authorities. For each 
aspect there are of course minimal requirements, and 
a number of remaining questions may be easily 
solved. Major discussions almost always concern the 
balance between the clinical benefit and the (poten­
tial) toxicity. In order to make a proper judgement it is 
of utmost importance that the pivotal clinical studies 
make use of relevant outcome criteria. The choice of 
these criteria must be thoroughly argumented. As dis­
cussed here, the percentage responders, according to
pre-defined criteria, in comparative add-on and 
monotherapy studies, is considered a major parame­
ter. The criteria should be based on expert knowledge 
on the patient and his disease, and should focus on 
major benefit for the patient. For proper judgement 
of the side effect pattern, and hence the efficacy/tox­
icity balance, monotherapy studies are considered of 
great importance. Although opinions on some of 
these topics differ, the common goal of industry, 
authorities and medical practitioners remains to get 
available effective and safe medicaments in order to 
improve the treatment of patients suffering from epi­
leptic seizures.
With that idea in mind it is difficult to justify that 
certain clinical trials are only set up to satisfy the regu­
latory authorities and that other trials have to be per­
formed later on to convince the clinical practitioners 
of the useful place of the new drug among the exist­
ing therapies. This gap in design and outcome 
parameters between pre-registration and post- regis­
tration trials, as it is generally perceived, needs to be 
bridged as soon as possible; ongoing discussions 
between scientists and clinicians from the parties 
involved may be helpful.
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